Literature DB >> 24903195

Growth-differentiation factor 15 and osteoprotegerin in acute myocardial infarction complicated by cardiogenic shock: a biomarker substudy of the IABP-SHOCK II-trial.

Georg Fuernau1, Christian Poenisch, Ingo Eitel, Suzanne de Waha, Steffen Desch, Gerhard Schuler, Volker Adams, Karl Werdan, Uwe Zeymer, Holger Thiele.   

Abstract

AIMS: This study investigates the role of osteoprotegerin (OPG) and growth-differentiation factor 15 (GDF-15) as predictors of outcome in cardiogenic shock (CS) complicating acute myocardial infarction. The novel biomarkers OPG and GDF-15 have shown prognostic impact in various cardiovascular diseases including myocardial infarction. In acute myocardial infarction complicated by CS, the diagnostic and prognostic impact of these biomarkers has not been investigated yet. OPG and GDF-15 may have additional prognostic impact on early prognosis assessment, being potentially useful for decision-making in CS. METHODS AND
RESULTS: In the randomized Intra-aortic Balloon Pump in cardiogenic Shock II (IABP-SHOCK II)-trial, 600 patients with CS complicating acute myocardial infarction undergoing early revascularization were assigned to therapy with or without IABP. Within a pre-defined substudy, blood samples were collected from 190 patients during PCI. GDF-15 and OPG serum levels were measured with standard enzyme-linked immunosorbent assay kits. Patients with GDF-15 and OPG levels greater than the median showed higher rates of death at 30 days by χ(2) testing (OPG, 51% vs. 32%, P = 0.01; GDF-15, 52% vs. 31%, P = 0.005) and log rank testing [GDF-15, hazard ratio (HR) 1.88, 95% confidence interval (CI) 1.21-2.94; P = 0.005; OPG, HR 1.74, 95% CI 1.11-2.71; P = 0.01]. Both markers were significantly predictive of 30-day mortality in univariable logistic regression analysis. In a multivariable logistic stepwise regression model, GDF-15, TIMI (Thrombolysis In Myocardial Infarction) flow grade <3 after PCI, age, LVEF, and serum lactate remained significant predictors of 30-day mortality.
CONCLUSION: GDF-15 on admission is a significant independent predictor of short-term mortality in infarct-related CS. Trail registration: NCT00491036.
© 2014 The Authors. European Journal of Heart Failure © 2014 European Society of Cardiology.

Entities:  

Keywords:  Cardiogenic shock; Growth-differentiation factor 15; Myocardial infarction; Osteoprotegerin; Prognosis

Mesh:

Substances:

Year:  2014        PMID: 24903195     DOI: 10.1002/ejhf.117

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  14 in total

1.  [Hypoxic hepatitis in cardiogenic shock : Incidence, laboratory detection and prognosis].

Authors:  C Jung; G Fürnau
Journal:  Med Klin Intensivmed Notfmed       Date:  2017-06-14       Impact factor: 0.840

2.  Incidence, laboratory detection and prognostic relevance of hypoxic hepatitis in cardiogenic shock.

Authors:  Christian Jung; Georg Fuernau; Ingo Eitel; Steffen Desch; Gerhard Schuler; Malte Kelm; Volker Adams; Holger Thiele
Journal:  Clin Res Cardiol       Date:  2016-12-08       Impact factor: 5.460

3.  Association of Lymphocyte to Monocyte Ratio and Risk of in-Hospital Mortality in Patients with Cardiogenic Shock: A Propensity Score Matching Study.

Authors:  Zhengwei Zhang; Qionghua Hu; Tianyang Hu
Journal:  Int J Gen Med       Date:  2021-08-12

4.  Cardiac Biomarkers and Risk of Atherosclerotic Cardiovascular Disease in Patients with CKD.

Authors:  Benjamin Lidgard; Leila Zelnickv; Amanda H Anderson; Harold Feldman; Alan Go; Jiang He; Mayank Kansal; Madhumita Jena Mohanty; Rupal Mehta; Michael G Shlipak; Elsayed Soliman; Matt R Weir; Nisha Bansal
Journal:  Kidney360       Date:  2022-03-02

Review 5.  Laboratory Predictors of Prognosis in Cardiogenic Shock Complicating Acute Myocardial Infarction.

Authors:  Tamilla Muzafarova; Zuzana Motovska
Journal:  Biomedicines       Date:  2022-06-05

6.  Growth differentiation factor-15 (GDF-15), novel biomarker for assessing atrial fibrosis in patients with atrial fibrillation and rheumatic heart disease.

Authors:  Yong-Ming Zhou; Ming-Jiang Li; Yan-Li Zhou; Le-Le Ma; Xin Yi
Journal:  Int J Clin Exp Med       Date:  2015-11-15

7.  Culprit lesion location and outcome in patients with cardiogenic shock complicating myocardial infarction: a substudy of the IABP-SHOCK II-trial.

Authors:  Georg Fuernau; Karl Fengler; Steffen Desch; Ingo Eitel; Franz-Josef Neumann; Hans-Georg Olbrich; Antoinette de Waha; Suzanne de Waha; Gert Richardt; Marcus Hennersdorf; Klaus Empen; Rainer Hambrecht; Christian Jung; Michael Böhm; Janine Pöss; Ruth H Strasser; Steffen Schneider; Taoufik Ouarrak; Gerhard Schuler; Karl Werdan; Uwe Zeymer; Holger Thiele
Journal:  Clin Res Cardiol       Date:  2016-07-04       Impact factor: 5.460

Review 8.  Novel biomarkers for cardiovascular risk prediction.

Authors:  Juan Wang; Guo-Juan Tan; Li-Na Han; Yong-Yi Bai; Miao He; Hong-Bin Liu
Journal:  J Geriatr Cardiol       Date:  2017-02       Impact factor: 3.327

Review 9.  Predictors of Outcomes in Myocardial Infarction and Cardiogenic Shock.

Authors:  Deepak Acharya
Journal:  Cardiol Rev       Date:  2018 Sep/Oct       Impact factor: 2.644

10.  Serum Concentrations of Osteogenesis/Osteolysis-Related Factors and Micro-RNA Expression in ST-Elevation Myocardial Infarction.

Authors:  Tomasz Jadczyk; Tomasz Francuz; Wojciech Garczorz; Malgorzata Kimsa-Furdzik; Mieczyslaw Dutka; Ewa Gaik; Katarzyna Gruszczynska; Marcin Syzdol; Wojciech Wanha; Radoslaw Kurzelowski; Joanna Fluder; Zdenek Starek; Wojciech Wojakowski
Journal:  Cardiol Res Pract       Date:  2019-06-02       Impact factor: 1.866

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.